Humana (NYSE:HUM) Given “Outperform” Rating at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Humana (NYSE:HUM) in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a $283.00 price objective on the insurance provider’s stock.

Several other brokerages have also issued reports on HUM. Wells Fargo & Company dropped their price objective on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price target on shares of Humana in a report on Wednesday. TD Cowen lifted their price objective on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Piper Sandler lifted their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Finally, Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and lifted their price target for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $293.05.

Humana Trading Up 0.3 %

Shares of Humana stock opened at $253.61 on Wednesday. The firm has a market capitalization of $30.54 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 2.11 and a beta of 0.56. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a 50 day moving average of $271.83 and a 200 day moving average of $295.17.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, research analysts predict that Humana will post 16.11 earnings per share for the current year.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Creative Financial Designs Inc. ADV grew its holdings in shares of Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 61 shares in the last quarter. FPC Investment Advisory Inc. bought a new position in Humana during the fourth quarter worth about $27,000. Centricity Wealth Management LLC acquired a new stake in Humana during the fourth quarter worth approximately $30,000. Ashton Thomas Securities LLC acquired a new stake in Humana during the third quarter worth approximately $31,000. Finally, Your Advocates Ltd. LLP raised its position in shares of Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.